| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3997594 | Supportive Cancer Therapy | 2006 | 4 Pages |
Abstract
Bevacizumab is the first successful example of targeting the vasculature for the treatment of solid tumors. Although generally well tolerated in combination with different chemotherapy regimens, bevacizumab has side effects that are unique to this class of agents. In this review, we discuss the side effects associated with bevacizumab and potential treatments to ameliorate these toxicities.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
